Analgesics in Ireland - New Market Study Published

Branded products continue to dominate analgesics in Ireland in 2015. As is the case with other categories within consumer health, brand loyalty remains significant, with a continuing perception of branded products offering higher overall quality and pain relief than many generic offerings. It is noteworthy, however, that in June 2013 the Health Service Executive (HSE) introduced reference pricing in an attempt to drive down the cost of Irish medicines, which are considered to be some of the most expensive within the EU. Lists of generic products are kept by pharmacists in order to offer their customers cheaper alternatives to branded products. This was done chiefly to alleviate the cost to the state of medical card prescriptions but it obviously affects the OTC category similarly. Its influence has been minimal however, with limited OTC penetration, and Ireland remains one of the most expensive EU countries in which to purchase generic medicines, as well as branded ones.

Full Report Details at
- http://www.fastmr.com/prod/1082072_analgesics_ireland.aspx?afid=301

Competitive Landscape

Reckitt Benckiser Ireland remains the country’s leading player in analgesics in 2015, chiefly owing to the popularity of its Nurofen brand. With increasing apprehension among consumers as to the side effects of products containing acetaminophen and codeine, consumer preference for ibuprofen products such as Nurofen remains strong.

Industry Prospects

Analgesics in Ireland is expected to increase at a constant 2015 value CAGR of 1% over the forecast period. Key brands will very likely remain prominent and well represented. Private label and generic products should continue to make small inroads into the category over the same period but may continue to find growth constrained by strong brand loyalty towards more trusted mainstream products. Competition among branded analgesics products should help maintain relatively stable unit prices, which in turn should further temper the likelihood of any significant impact from generic products. An important factor limiting growth within the category remains the growing awareness amongst the public of the potential health considerations of analgesics, a perception that was reinforced by the change in status in 2013 of products containing codeine.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Ireland with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Ireland, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Ireland market research report includes:

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Analgesics in South Korea
- Analgesics in Tunisia
- Analgesics in the United Arab Emirates
- Analgesics in Mexico
- Analgesics in Algeria